Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Magné, N.
Right arrow Articles by Bussière, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Magné, N.
Right arrow Articles by Bussière, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 32:202-205 (2002)
© 2002 Foundation for Promotion of Cancer Research

Disposition of Radioiodine 131I Therapy for Thyroid Carcinoma in a Patient with Severely Impaired Renal Function on Chronic Dialysis: a Case Report

Nicolas Magné1, Jacques Magné2, Jean Bracco3 and Françoise Bussière2,+

Departments of 1 Medical Oncology and 2 Nuclear Medicine, Centre Antoine Lacassagne, Nice and 3 Department of Nephrology, Hôpital Pasteur, Nice, France

The aim of this study was to analyze the disposition of radioiodine used for the ablation of thyroid remnants after radical surgery for a differentiated thyroid carcinoma in a patient on chronic hemodialysis in order to deliver the optimal 131I dose to improve the healing rate in these rare cases and to serve as a useful reference to other health care professionals who might face a similar dilemma. A 50 mCi dose of 131I was administered orally and dialysis sessions were performed 24, 72 and 144 h after therapy. Patient effluent dialyzate waste samples were collected and blood radioactivity analyses were performed at each dialysis session. The 131I disposition half-life was 2.7 ± 0.8 h. The amounts of remnant radioactivity in total body patient were 58.7, 38.9 and 27.1%, respectively, after each of the three dialysis sessions and the effective period calculated was 1.4 days. The extents of water purification in blood were 69.7, 47.9 and 22.7% at the beginning of each dialysis and 37.7, 42.8 and 18.1% at the end of each dialysis. Effective periods of radioiodine for thyroid cancer in a patient on hemodialysis resulted in rapid iodine clearance, thereby reducing the effective radiation dose and promoting the need to use larger treatment doses. Hemodialysis was safe and effective during treatment with radioiodine.

+ For reprints and all correspondence: Nicolas Magné, Oncopharmacology Unit, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice Cedex 2, France. E-mail: nicolas_magne@hotmail.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
P Iglesias and J J Diez
Thyroid dysfunction and kidney disease
Eur. J. Endocrinol., April 1, 2009; 160(4): 503 - 515.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
C. Stabroth and F. C. Luft
A glowing report on dialysis
Nephrol. Dial. Transplant., May 1, 2005; 20(5): 1005 - 1006.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.